EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Pharmacophore to Warhead: NAD + ‐Targeting Triazoles as Mechanism‐Based Sirtuin Inhibitors

Florian Friedrich iD, Marat Meleshin iD, Niklas Papenkordt iD, Lena Gaitzsch iD, Isabel Prucker iD, Marco Borso iD, Jan Ruprecht iD, Christopher Vorreiter iD, Sabrina Rast, Lin Zhang iD, Matthias Schiedel iD, Wolfgang Sippl iD und 5 weitere

Angewandte Chemie International Edition · 2025

DOI: 10.1002/anie.202516782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Florian Friedrich und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104, Freiburg, Germany. Hauptthemen laut MEDLINE: Triazoles, NAD, Sirtuins, Enzyme Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sirtuins (SIRTs) are nicotinamide adenine dinucleotide (NAD + )‐dependent lysine deacylases linked to key physiological and disease processes. Here, we report a new class of mechanism‐based 1,2,3‐triazole inhibitors that hijack SIRT catalysis by forming stalled triazolium– or triazole–ADP‐ribose (ADPR) adducts derived from the cofactor NAD + . These trapped adducts inhibit the enzyme without covalent protein modification, prompting us to term the compounds “Sirtuin Trapping Ligands” (SirTraps). X‐ray crystallography and kinetics, together with mass spectrometry confirming adduct formation both in vitro and in cellulo, reveal that the triazole N3 of peptide‐ and small‐molecule‐based SirTraps triggers nucleophilic attack at C1’ of the nicotinamide riboside moiety of NAD⁺, mimicking the first deacylation step. Adduct formation critically depends on precise triazole positioning within the acyl‐lysine channel and can be tuned through scaffold design, enabling potent and isoform‐selective inhibition. Unlike thiocarbonyl‐based NAD⁺‐targeting SIRT inhibitors, which may suffer from instability and off‐target effects, SirTraps combine high stability, synthetic accessibility, and structural tunability, while demonstrating nanomolar cellular target engagement confirmed by NanoBRET assays. Beyond SIRTs, this inhibition strategy may extend to other NAD⁺‐dependent enzymes, including ADP‐ribosyltransferases, opening new avenues for mechanism‐driven drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesNADSirtuinsEnzyme InhibitorsHumansCrystallography, X-RayMolecular StructureModels, MolecularPharmacophore

Stichwörter der Autor:innen

Covalent adductDrug discoveryInhibitorsSirtuinsTriazoles

Substanzen

TriazolesNADSirtuinsEnzyme Inhibitors

Autor:innen und Institutionen

  • Institute of Pharmaceutical Sciences, University of Freiburg, Albertstr. 25, 79104, Freiburg, Germany.
  • Department of Enzymology, Charles Tanford Protein Center, Institute of Biochemistry and Biotechnology, Martin-Luther-University of Halle-Wittenberg, Kurt-Mothes-Straße 3a, 06120, Halle, Germany.
  • Institute of Organic Chemistry, University of Freiburg, Albertstr. 21, 79104, Freiburg, Germany.
  • Biomedical Center, Medizinische Fakultät, Ludwigs-Maximilians Universität, Großhaderner Str. 9, Plangegg-Martinsried, 82152, Germany.
  • Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120, Halle, Germany.
  • Deutsches Konsortium für Translationale Krebsforschung (DKTK), 79104, Freiburg, Germany.

ORCID-Profile: Florian Friedrich, Marat Meleshin, Niklas Papenkordt, Lena Gaitzsch, Isabel Prucker, Marco Borso, Jan Ruprecht, Christopher Vorreiter, Lin Zhang, Matthias Schiedel, Wolfgang Sippl, Axel Imhof, Henning J Jessen, Oliver Einsle, Mike Schutkowski, Manfred Jung

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Friedrich, F., Meleshin, M., Papenkordt, N., Gaitzsch, L., Prucker, I., Borso, M., Ruprecht, J., Vorreiter, C., Rast, S., Zhang, L., Schiedel, M., Sippl, W., Imhof, A., Jessen, H. J., Einsle, O., Schutkowski, M., & Jung, M. (2025). From Pharmacophore to Warhead: NAD + ‐Targeting Triazoles as Mechanism‐Based Sirtuin Inhibitors. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202516782

Vancouver

Friedrich F, Meleshin M, Papenkordt N, Gaitzsch L, Prucker I, Borso M, et al. From Pharmacophore to Warhead: NAD + ‐Targeting Triazoles as Mechanism‐Based Sirtuin Inhibitors. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202516782

BibTeX
@article{Friedrich2025,
  author = {Friedrich, Florian and Meleshin, Marat and Papenkordt, Niklas and Gaitzsch, Lena and Prucker, Isabel and Borso, Marco and Ruprecht, Jan and Vorreiter, Christopher and Rast, Sabrina and Zhang, Lin and Schiedel, Matthias and Sippl, Wolfgang and Imhof, Axel and Jessen, Henning J and Einsle, Oliver and Schutkowski, Mike and Jung, Manfred},
  title = {From Pharmacophore to Warhead: NAD + ‐Targeting Triazoles as Mechanism‐Based Sirtuin Inhibitors},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  doi = {10.1002/anie.202516782}
}
Kostenlos starten →